Combination antihypertension therapy: The “underresearched” combinations

Decrease of blood pressure (BP) and its maintenance on target level is the main factor for cardiovascular mortality and morbidity reduction in hypertensive patients. For effective BP decrease most patients need combination therapy. The article is focused on benefits and adverse events of some combinations. In details an issue considered, on the combination of beta-blocker and renin-angiotensine-aldosteron system blocker, which, by the data from Russian observational programs, is the leader among two-component combinations. © 2017, Silicea-Poligraf, All right reserved.

Authors
Kotovskaya Y.V. 1, 2 , Runikhina N.K.2 , Ostapenko V.S.2
Publisher
Silicea-Poligraf
Number of issue
5
Language
Russian
Pages
132-139
Status
Published
Volume
145
Year
2017
Organizations
  • 1 Peoples’ Friendship University of Russia, Moscow, Russian Federation
  • 2 N. I. Pirogov Russian National Research Medical University (RNRMU), Russian Gerontology Scientific-Clinical Center, Moscow, Russian Federation
Keywords
Adverse events; Arterial hypertension; Combination therapy
Date of creation
19.10.2018
Date of change
19.10.2018
Short link
https://repository.rudn.ru/en/records/article/record/5825/
Share

Other records